Unveiling the P2X7 receptor: Exploring its mechanisms, pathogenic role in ocular diseases, and emerging therapeutic

Kai-Yang Chen1, Hoi-Chun Chan2, Chi-Ming Chan3

  • 1School of Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan.

PubMed

Insights

The P2X7 receptor (P2X7R) regulates retinal function and disease. Targeting P2X7R offers potential therapies for various blinding eye conditions by reducing inflammation and cell death.

Area of Science:

  • Ophthalmology
  • Immunology
  • Cell Biology

Background:

  • Purinergic signaling via extracellular ATP (eATP) and P2 receptors is integral to physiological and pathological processes.
  • The P2X7 receptor (P2X7R), a ligand-gated cation channel, is a key mediator of inflammation, cell death, and immune responses.
  • P2X7R is widely expressed in retinal cells, influencing visual function and retinal degeneration.

Purpose of the Study:

  • To review the role of P2X7R in the pathogenesis of major retinal diseases.
  • To highlight P2X7R's contribution to inflammatory and degenerative processes in the retina.
  • To explore the therapeutic potential of targeting P2X7R for vision preservation.

Main Methods:

  • Literature review of studies investigating P2X7R in retinal diseases.
  • Analysis of P2X7R's molecular mechanisms in retinal cell function and pathology.
  • Synthesis of evidence linking P2X7R activation to disease progression.

Main Results:

  • P2X7R activation promotes inflammation, oxidative stress, apoptosis, and immune dysregulation in the retina.
  • Specific roles of P2X7R in age-related macular degeneration (AMD), Behçet's disease (BD), diabetic retinopathy (DR), glaucoma, retinitis pigmentosa (RP), uveitis, Stargardt's disease (STGD), and toxoplasmosis were identified.
  • P2X7R contributes to retinal pigment epithelium (RPE) degeneration in AMD, vascular proliferation in DR, neuroinflammation in glaucoma, and photoreceptor loss in RP.

Conclusions:

  • P2X7R is a significant contributor to the pathophysiology of diverse retinal diseases.
  • Modulating P2X7R activity presents a promising therapeutic strategy for treating blinding conditions.
  • Targeting P2X7R could offer novel approaches to preserve retinal function and prevent vision loss.

Related Concept Videos

Ligand-Gated Ion Channel Receptor: Gating Mechanism01:30

Ligand-Gated Ion Channel Receptor: Gating Mechanism

Ligand-gated ion channels are transmembrane proteins that play a vital role in intercellular communication and functions of the nervous system. They allow the influx of ions across the membrane once the neurotransmitter binds, allowing the subsequent transmission of electrical excitation across the neurons. Other ligand-gated ion channels, like the γ-aminobutyric acid (GABA) receptor, permit anions like chloride into the cells on the binding of the GABA molecule. Their entry into the cell...
2.6K
Open Angle Glaucoma: Treatment01:27

Open Angle Glaucoma: Treatment

In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
577
Direct-Acting Cholinergic Agonists: Therapeutic Uses01:11

Direct-Acting Cholinergic Agonists: Therapeutic Uses

Direct-acting cholinergic agonists have many therapeutic uses in various medical fields. Choline esters, including acetylcholine, have limited clinical utility due to their non-selectivity and short duration of action. Still, acetylcholine and carbachol are applied topically during ophthalmologic surgery to induce miosis. Pilocarpine, a muscarinic and ganglionic stimulator, effectively treats open-angle glaucoma and alleviates xerostomia and dry mouth caused by radiotherapy or Sjögren...
889